Novo Nordisk A/S - share repurchase programme
08 Juli 2024 - 3:18PM
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 08 July 2024 – On 6 May
2024, Novo Nordisk initiated a share repurchase programme in
accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission
Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.2 billion in the
period from 7 May 2024 to 5 August 2024.
Since the announcement 01 July 2024, the following transactions
have been made:
|
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
|
Accumulated, last announcement |
1,327,375 |
|
1,260,635,397 |
| 1 July
2024 |
36,500 |
1,000.38 |
36,513,702 |
| 2 July
2024 |
41,500 |
996.38 |
41,349,738 |
| 3 July
2024 |
39,000 |
979.48 |
38,199,570 |
| 4 July
2024 |
34,000 |
968.79 |
32,938,742 |
| 5 July
2024 |
33,970 |
973.80 |
33,080,012 |
|
Accumulated under the programme |
1,512,345 |
|
1,442,717,161 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
11,612,159 B shares of DKK 0.10 as treasury shares, corresponding
to 0.3% of the share capital. The total amount of A and B shares in
the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 05 July 2024, Novo Nordisk has since 6 February 2024
repurchased a total of 10,246,595 B shares at an average share
price of DKK 875.46 per B share equal to a transaction value of DKK
8,970,451,933.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 66,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information.
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
|
Investors: |
|
| Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
| Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656azey@novonordisk.com |
| Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Ida
Melvold Gjøsund+45 3077 5649 idmg@novonordisk.com |
Company announcement No 51 / 2024
- CA240708_Share repurchase
- 240708 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
